medRxiv preprint doi: [https://doi.org/10.1101/2024.11.16.24317338;](https://doi.org/10.1101/2024.11.16.24317338) this version posted November 18, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a CC-BY 4.0 International license.

It is made available under a CC-BY 4.0 International license.

24 - Email : daniel.prietoalhambra@ndorms.ox.ac.uk

25 Abstract

- 26 **INTRODUCTION:** While preclinical studies suggest that Phosphodiesterase 5 (PDE5)
- 27 inhibition may reduce cognitive impairment, findings from observational studies on
- 28 whether PDE5 inhibitors reduce Alzheimer's disease (AD) risk have been inconsistent.
- 29 **METHODS:** A two-sample *cis-*Mendelian Randomisation (MR) analysis was conducted
- 30 to estimate the causal effect of PDE5 inhibition on AD risk. The analysis was performed
- 31 across four different genome-wide association studies (GWAS) of AD to enhance
- 32 evidence reliability through triangulation. Additionally, a sex-stratified MR analysis using
- 33 data from UK Biobank was performed to assess potential sex-specific effects.
- 34 **RESULTS:** No evidence of a causal association between PDE5 inhibition and AD risk
- 35 was found in the main analyses or sex-stratified analysis.
- 36 **DISCUSSION:** MR findings suggest that PDE5 inhibitors are unlikely to decrease the
- 37 risk of AD. Further research is needed to thoroughly understand the impact of PDE5
- 38 inhibitors on the risk of Alzheimer's disease.

39 Keywords

40 Alzheimer's disease, Mendelian randomisation, PDE-5, Phosphodiesterase-5, 41 dementia, sildenafil.

It is made available under a CC-BY 4.0 International license.

42 1. BACKGROUND

43 Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most 44 common cause of dementia. It is characterised by the accumulation of beta-amyloid 45 plaques and neurofibrillary tangles in the brain, leading to a gradual deterioration of 46 cognitive function and memory¹. With the global increase in life expectancy, AD is 47 rapidly emerging as a significant public health thread worldwide².

48

49 Recently, the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK 50 approved Lecanemab for treating adults in the early stages of $AD³$. While the treatment 51 has been shown effective for slowing the disease progression, the National Institute for 52 Health and Care Excellence (NICE) has not recommended its availability on the NHS, 53 arising concerns about its cost-effectiveness⁴. There is therefore still a scarcity of drugs 54 that can effectively treat or prevent AD.

55

56 Several studies have identified numerous modifiable risk factors that may be associated 57 with AD^5 , offering the potential opportunity for intervention through drug repurposing 58 strategies⁶. This strategy aims to identify new therapeutic uses for existing drugs that 59 have already been approved. In terms of cost-effectiveness, reduced drug-development 60 time, and lower risk of failure, repurposing presents a highly advantageous strategy. 61 Within this context, antihypertensive and related medications have been previously 62 highlighted as promising candidates for AD prevention⁷. Specifically, 63 Phosphodiesterase 5 (PDE5) inhibitors have gained growing interest due to their 64 botential neuroprotective effects⁸.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

65

74 Conflicting results have also been reported in observational studies^{13,14}, where 75 confounding, time-related bias or reverse causation can play a key role. Alternatively, 76 Mendelian randomisation (MR) can offer a robust approach to investigate causal 77 relationships overcoming some of the limitations of observational research, as well as 78 allowing for triangulation of evidence^{15,16}. Specifically, drug target MR is an analytical 79 method that uses genetic variants within or near the gene encoding the risk factor (*cis*-80 variants) as instruments to proxy the exposure^{15,17}. Since alleles are randomly allocated 81 during meiosis, this approach can minimise the risk of confounding that typically affects 82 traditional observational studies, provided that all underlying MR assumptions are met. 83

84 In this study, we performed a two-sample *cis-*MR analysis to estimate the causal effect 85 of genetically proxied PDE5 inhibition and the risk of AD. To investigate this, we have 86 used diastolic blood pressure as a surrogate biomarker. Furthermore, we also

87 conducted a stratified by sex MR analysis, where we used UK Biobank (UKB) to identify 88 AD cases.

89 2. METHODS

90 2.1. Study design

91 We performed a two-step *cis*-Mendelian Randomisation analysis to estimate the causal 92 effect between genetically proxied PDE5 inhibition and AD risk. We scaled the effect of 93 PDE5 inhibition based on a surrogate biomarker -diastolic blood pressure^{15,18}. We used 94 four different genome-wide association study (GWAS) of AD, each one differing by the 95 sample size, heritability value, and the use of by-proxy cases. Additionally, we 96 performed a sex-stratified analysis using UKB dataset to identify AD cases. Figure 1 97 summarises the study design.

98 2.2. Data sources

99 **2.2.1. Variant-risk factor estimates**

100 Variant-exposure estimates were extracted from a GWAS of diastolic blood pressure¹⁹. 101 We used diastolic blood pressure (DBP) instead of systolic blood pressure (SBP) as 102 PDE5 inhibition is known to have a greater impact on the former¹¹. Evangelou *et al.* 103 GWAS meta-analysed 77 cohorts (n = 757,601) participating in the International 104 Consortium for Blood Pressure Genome $(ICBP)^{20}$ and UKB²¹. Blood pressure for each 105 individual in the participating cohorts was measured in mmHg using either manual or 106 automated readings. All participating cohorts adjusted for age, age², sex, body mass 107 index, and study-specific covariates. UKB cohort further corrected BP measures for 108 those with self-reported medication use. Further information about study design,

It is made available under a CC-BY 4.0 International license.

109 participants, and genotype quality control of this GWAS can be found in the original

110 publication

111

112 GWAS estimates were measured in mmHg change per effect allele, and SNPs positions

113 were reported in hg19/GRCh37 coordinates.

114 **2.2.2. Variant-outcome estimates**

115 Genetic variant-outcome associations were derived from the AD GWAS published by 116 Lambert *et al.²²* which conducted a two-stage meta-analysis of GWAS in individuals of 117 European ancestry. We used estimates from stage 1, which consisted of 54,162 118 participants (17,008 AD cases and 37,154 controls) containing 7,055,881 genotyped 119 and imputed variants. Further details of the databases included in this meta-analysis 120 can be found in Supplement (Note 1 and Table 1). As secondary outcomes, we used

121 three different AD GWAS: Rojas *et al.*²³ (N = 409,435), Bellenguez *et al.*²⁴ (N =

122 $487,511$) and Wightman *et al.²⁵* (N = 398,108). All of them included only European

123 participants. More details about the study populations can be found in the respective

124 original publications and in supplementary (Note 1 and Table 1).

125

126 We included these additional AD GWAS as secondary outcomes to validate our main 127 study results. We did this due to the following reasons: (1) although they have bigger 128 sample sizes, these AD GWAS have smaller SNP-based heritability value compared to 129 Lambert AD GWAS; (2) the AD GWAS conducted by Rojas and Bellenguez contain a 130 proportion of by-proxy-cases for AD; and, 3) Rojas and Bellenguez GWAS included

It is made available under a CC-BY 4.0 International license.

- 131 UKB, as well as Evangelou blood pressure GWAS, and we wanted to avoid sample 132 overlap as can lead to biased results in the presence of weak instruments²⁶. 133 134 All GWAS estimates were reported on the *log*(OR) scale. SNP coordinates were in 135 hg19/GRCh37 assembly, except Rojas *et al.* GWAS, which was in the hg38/GRCh38 136 assembly. We aligned the coordinates of this GWAS from hg38/GRCh38 to 137 hg19/GRCh37 using LiftOver 27 . 138 139 In the sex-specific analysis, we used UKB 21 to estimate the variant-outcome effects. 140 UKB is a large population-based cohort study of over 500,000 participants aged 40 to 141 69 at recruitment (2006 and 2010). UKB collected lifestyle data and biological samples 142 \cdot for genotyping²⁸. Genotyping, performed by Affymetrix, includes 784,256 autosomal 143 variants. Imputation was done using the Haplotype Reference Consortium and UK10K 144 panels, covering 93 million SNPs. Health outcomes, including dementia and AD, were 145 ascertained using validated algorithms combining baseline data and linked hospital and 146 death records, with follow-up data until December 2022 147 (https://biobank.ndph.ox.ac.uk/showcase/refer.cgi?id=460). In total, there are around 148 10,000 of dementia cases recorded in UKB. 149 2.3. Statistical analysis
- 150 **2.3.1. Instrument selection**

151 Instrumental variables used in MR must (1) be associated with the exposure, (2) not be 152 associated with the outcome through confounding pathways, and (3) not affect the 153 outcome except via the exposure²⁹. Instrumental variables to proxy PDE5 inhibition

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

163 study (Table 1). The variant with strongest association (i.e., lowest P-Value) was 164 rs66887589 (Beta = -0.16 respect allele T, 95%CI = -0.2 to -0.12). Variant rs17355550

165 was the one with weakest association with DBP (Beta = -0.14 respect allele C, 95%CI = 166 -0.23 to -0.04).

167

168 **2.3.2. Main analysis**

169 Mendelian randomisation estimates were calculated using the inverse-variance 170 weighted method accounting for correlation between variants 31 . We used the linkage 171 disequilibrium matrix corresponding to European ancestry participants with the 1000 172 Genomes reference panel phase 3. Exposure alleles and outcome alleles were 173 harmonised with respect to the linkage disequilibrium matrix. All MR estimates were 174 reported as OR. We scaled our estimates to represent a daily 100mg dose of sildenafil, 175 knowing that this amount decreases 5.5mmHg DBP.

It is made available under a CC-BY 4.0 International license.

177 **2.3.3. Sex-stratified analysis**

178 As AD is more prevalent in women compared to men³², we repeated the main analysis 179 separately in females and males. We used the same variant-risk factor GWAS as in the 180 main analysis (described in section Methods/Data sources/Variant-risk factor 181 estimates), as previous research showed that SNP effects were identical for both, the 182 mixed and the specific sex analysis³³. We used UKB to calculate genetic variants-AD 183 associations separately for both females and males. 184 185 We used the algorithmically-defined dementia types to restrict our UK Biobank cohort to 186 participants without other forms of dementia (frontotemporal, vascular, or all cause of 187 dementia – including only those with AD-). AD cases were classified as those with an 188 AD report, whereas AD controls were those without one. All UKB variable fields IDs 189 used in the study can be found in Supplementary Table 2. 190 191 We estimated the effect size of the genetic instruments on the algorithmically defined

192 AD (separately for each sex) using a logistic regression. We used age at first 193 assessment, the genetic batch, and the first 10 genetic principal components as 194 covariates in the model. Beta coefficients obtained from the two different regressions 195 were used later for computing the MR estimates. 196

197 MR effects were reported as OR per 5.5mmHg decrease in DBP.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

198 2.4. Sensitivity analysis

199 **2.4.1. Two-Step** *cis-***Mendelian randomization**

- 200 To account for any potential horizontal pleiotropic effects, we performed two-step *cis*-
- 201 MR. This approach employs a two-step mediation strategy to account for potential
- 202 bleiotropic pathways by adjusting variant-outcome associations³⁴. Hence, this approach
- 203 is used to adjust our MR estimates for any effect mediated by other related traits.

204

- 205 We adjusted our analysis for body mass index (BMI), as its inclusion as a covariate in
- 206 the DBP GWAS can induce collider bias 35 .

207 **2.4.2. Leave-one-out analysis**

208 To assess whether the results from the main analysis were driven by a single 209 instrument, we performed leave-one-out analysis³⁶. In this approach, one SNP from the 210 instrumental set is removed and the estimate causal effect is re-calculated. We 211 performed this analysis for each one of the AD GWAS included in this study.

212 2.5. Software and implementation

213 We used R (version 3.2) for this study. The main packages used included 214 *TwoSampleMR*³⁷, *TwoStepCisMR*³⁴, *coloc*³⁸, liftOver²⁷, dplyr³⁹, and ggplot2⁴⁰. This 215 manuscript was written according to the STROBE-MR reporting quidelines⁴¹.

216

217 All the analytical code can be found in the public GitHub repository: 218 https://github.com/oxford-pharmacoepi/PDE5_AD_MendelianRandomisation

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

219 3. RESULTS

220 3.1. Main analysis

221 We found little evidence of an association between genetically proxied PDE5 inhibition 222 and AD risk using Lambert's *et al*. GWAS (OR = 1.00, 95% confidence interval 0.96 to 223 1.04, P-Value = 0.96). These results were consistent when using the other AD GWAS 224 data (Figure 2).

225

- 226 Refer to Supplementary Table 3 to see the linkage disequilibrium matrix employed.
- 227 Harmonised variant-risk factor and variant-outcome effects can be found in
- 228 Supplementary Table 4. SNPs effect on the exposure against SNPs effects on the
- 229 outcome (Lambert's *et al*) can be found in Supplementary Figure 1.

230 3.2. Sex-stratified analysis

231 From the 502,230 participants in UKB, we excluded 6,153 participants because they

232 were diagnosed with vascular dementia, frontotemporal dementia or other forms of

233 dementia (Supplementary Figure 2). After further restricting to individuals with

234 genotyped data, we obtained a cohort of 262,037 females with 2,030 AD cases, and a

235 cohort of 220,352 males with 1,722 cases. Baseline characteristics of the respective

236 cohorts can be found in Supplementary Table 5.

237

238 MR results for both sex were consistent with the main analysis (Supplementary Figure

239 3), showing no association between genetically proxied PDE5 inhibition and AD risk

240 (Male: scaled OR = 1.04, 95% CI = 0.97 to 1.11, P-Value = 0.3; Female: scaled OR =

241 0.95 , 95% CI = 0.88 to 1.03, P-Value = 0.2).

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

242 3.3. Sensitivity analyses

243 **3.3.1. Two-Step** *cis-***Mendelian randomization**

- 244 Results from the two-step *cis-*MR were consistent with the main findings
- 245 (Supplementary Table 6), suggesting that BMI did not induce bias to our results.

246 **3.3.2. Leave-one-out**

- 247 There was little evidence to suggest that any of the instruments was driven to the
- 248 obtained results was found in the leave-one-out analysis. All results were consistent
- 249 with the main findings (Supplementary Table 7).

250

251 4. DISCUSSION

252 In this study, we used drug target MR to investigate the association between genetically 253 proxied PDE5 inhibition and the risk of AD. Using DBP to scale PDE5 inhibition, our 254 analysis showed little evidence of an effect of PDE5 inhibition on AD risk using a variety 255 of AD GWAS datasets. Results stratifying by sex also showed no evidence of a causal 256 association.

257

258 PDE5 is an enzyme responsible for degrading cyclic guanosine monophosphate 259 (cGMP)⁴², a molecule that actives protein kinase G (PKG). PKG plays a key role in the 260 regulation of smooth muscle relaxation, particularly in blood vessels. In addition to its 261 vascular effects, the cGMP/PKG signalling have also been shown to play a role in 262 neuronal plasticity⁴³⁻⁴⁵. Animal models have shown the potential of sildenafil enhancing 263 memory and cognitive function⁴⁶⁻⁴⁹ while having other neuroprotective effects, such as

It is made available under a CC-BY 4.0 International license.

264 improving synaptic plasticity⁵⁰, or reducing amyloid burden⁴⁶. However, clinical studies 265 results' regarding sildenafil efficacy to enhance cognition have not been yet 266 conclusive¹², although it has been recently shown to improve brain blood flow⁸.

267

268 Interestingly, observational studies have also found contradictory results. In 2021, Fang 269 et al.¹³ developed an endophenotype network analysis where sildenafil was identified as 270 a candidate drug in AD. They further conducted an observational study that suggested a 271 reduction of 69% the risk of AD among sildenafil users compared to nonusers. This 272 result was not aligned with a new-user active comparator cohort study conducted by 273 Desai *et al.* (2022)¹⁴, where they did not find any evidence of an association between 274 sildenafil and endothelin receptor antagonist users in people with PAH. Strengths, 275 limitations and differences between the previous two observational studies have been 276 extensively discussed elsewhere^{14,51,52}, mainly pointing to issues regarding the target 277 population and the study design.

278

279 Our study presents genetic evidence that supports Desai *et al.*'s results. However, there 280 are significant differences in the interpretation of both studies. First, Desai and 281 colleagues included other dementias (vascular dementia, senile, pre-senile, or 282 unspecified dementia) rather than AD to define the outcome, which can bias the results 283 to the null if sildenafil has only impact on AD. In our study, we used different GWAS 284 studies for AD, each one with different definition. For example, the main study outcome 285 (Lambert's *et al.*²²) did include (although in small proportion) participants with mixed AD 286 and vascular dementia (Supplementary Note 1) to define AD, as well as Bellenguez *et*

It is made available under a CC-BY 4.0 International license.

287 *al.²⁴* definition. However, Wightman²⁵ and De Rojas²³ used a more specific definition for 288 AD. Second, they restricted the study population to participants with PAH to minimise 289 the risk of confounding by indication, reducing significantly the study population sample 290 size. This can result in a lack of statistical power and generalisability to the general 291 population, not only because of the sample size but also because, given the high 292 mortality rate among medicated PAH patients, it can be that participants did not live 293 long enough to develop AD. However, in our study we used Mendelian randomisation, 294 which assumes that alleles are randomised at meiosis, we could study the impact of 295 genetically proxied PDE5 inhibition, instrumented in a wider European population. Third, 296 whereas they studied the impact of sildenafil usage on AD, our study did not assess 297 that. Instead, we studied the effect of having lower levels of PDE5 in a lifelong time.

298

299 AD has been reported to be more prevalent in women³², whereas sildenafil is mainly 300 prescribed to men. Hence, we performed a sex-stratified analysis using data from UKB 301 to estimate the variant-outcome associations independently for males and females. Our 302 findings indicated that genetically proxied PDE5 inhibition was not associated with a 303 reduced risk of AD in either sex. However, both analyses were influenced by a 304 significant case-control imbalance ratios, with only around 0.8% of participants being 305 classified as cases. Hence, our sex-stratified analysis can be underpowered to detect 306 any association.

307

308 A previous observational study conducted only in men diagnosed with ED had identified 309 an association between the use of PDE5 inhibitors and decrease risk of AD^{53} . The

It is made available under a CC-BY 4.0 International license.

310 cohort study compared users of PDE5 inhibitors with non-users, based on the 311 assumption that patients continued the treatment after the initial prescription. However, 312 PDE5 inhibitors for ED are typically taken when required rather than regularly. This 313 intermittent use challenges the assumption that participants consistently followed up 314 with the treatment once prescribed, potentially impacting the study's conclusions.

315

316 Our study has several strengths that enhance the robustness of our findings. Firstly, we 317 used MR to triangulate evidence from previous observational evidence, which is known 318 to be less susceptible to unobserved confounding and reverse causation, compared to 319 traditional observational studies^{15,17}. Second, we used instrumental variables that have 320 been previously tested and validated using positive control outcomes, enhancing their 321 reliability. Third, we included different AD definitions, each one prone to different bias, in 322 the main analysis and obtained consistent evidence, ensuring the robustness of our 323 results. Additionally, we further performed a two-step *cis-*MR to adjust for potential 324 pleiotropic effect, where results were also consistent with the main analysis.

325

326 There are some limitations that must be considered when interpreting our results. First, 327 by using MR, we are studying the effect of small lifelong effects of lower PDE5 levels on 328 AD. However, PDE5 inhibitors are typically administered for a shorter time, in higher 329 doses and at a specific point in time. Thus, the effect estimates from this study should 330 not be interpreted as the effect of the pharmacological intervention, but as an 331 approximation of the direction of the causal effects. Second, we only included European 332 populations in our study (although in the sex-specific analysis we did not restrict to

333 increase the sample size, the proportion of non-white individuals was much smaller 334 compared to white individuals). Therefore, our results are potentially not generalisable 335 to other populations. Third, our model assumes that the effects of PDE5 inhibition are 336 linear across the dose-response range. Forth, although we included different AD GWAS 337 with different sources of bias, all of them relied on clinical diagnostic rather than 338 postmortem autopsy (which is known to be the gold standard to detect the underlying 339 cause of dementia). Hence, heterogeneity in our outcome might influence the results, as 340 different types of dementia can have different risk factors⁵⁴.

341

342 Our study provides genetic evidence that PDE5 inhibitors are unlikely to decrease the 343 risk of AD. Findings from this study have significant implications for our understanding 344 of AD pathophysiology and the identification of PDE5 inhibitors potential therapeutic 345 targets.

346 5. Data availability

347 All GWAS used are publicly available (see references to original publications and 348 Supplementary Table 1). UK Biobank individual-level source data can be accessed by 349 applying for access at http://ukbiobank.ac.uk/register-apply/. This research has been 350 conducted using the UK Biobank Resource under Application Number 98358.

351 6. Acknowledgements

352 The authors express sincere gratitude to all individuals who generously participated in 353 each one of the GWAS we have included in this study, as well as UK Biobank

It is made available under a CC-BY 4.0 International license.

354 participants. This work uses data provided by patients and collected by the NHS as part 355 of their care and support.

356

357 7. Conflicts of interest

358 DG is the Chief Executive Officer of Sequoia Genetics, a private limited company that 359 works with investors, pharma, biotech, and academia by performing research that 360 leverages genetic data to help inform drug discovery and development. DG has 361 financial interests in several biotechnology companies. DPA receives funding from the 362 UK National Institute for Health and Care Research (NIHR) in the form of a senior 363 research fellowship. DPA's group received partial support from the Oxford NIHR 364 Biomedical Research Centre. DPA's department has received grant/s from Amgen, 365 Chiesi-Taylor, Lilly, Janssen, Novartis, and UCB Biopharma. His research group has 366 received consultancy fees from AstraZeneca and UCB Biopharma. Amgen, Astellas, 367 Janssen, Synapse Management Partners, and UCB Biopharma have funded or 368 supported training programmes organised by DPA's department. All other authors 369 report no conflicts of interest.

370

371

. [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) It is made available under a

It is made available under a CC-BY 4.0 International license

373 **Table 1: Single nucleotide polymorphisms employed as instruments for the Mendelian randomisation analysis.**

374 Note: SNP = Single nucleotide polymorphism, SE = Standard error, EAF = effect allele frequency.

medRxiv preprint doi: [https://doi.org/10.1101/2024.11.16.24317338;](https://doi.org/10.1101/2024.11.16.24317338) this version posted November 18, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a CC-BY 4.0 International license.

GWAS

377

378 **Fig. 1: Scheme of the study design.** GWAS = Genome wide association study.

medRxiv preprint doi: [https://doi.org/10.1101/2024.11.16.24317338;](https://doi.org/10.1101/2024.11.16.24317338) this version posted November 18, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

380

381 **Fig. 2: Results from the Mendelian randomization**. Odds ratio is scaled to represent 382 100mg dose of sildenafil (which reduces 5mmHg diastolic blood pressure). Note: OR =

383 Odds ratio, CI = Confidence interval.

384

386 References

- 387 1. NHS. Alzheimer's disease. 2024; https://www.nhs.uk/conditions/alzheimers-388 disease/, 2024.
- 389 2. Alzheimer's A. 2016 Alzheimer's disease facts and figures. *Alzheimers Dement.* 390 2016;12(4):459-509.
- 391 3. GOV.UK. Lecanemab licensed for adult patients in the early stages of 392 Alzheimer's disease. 2024; https://www.gov.uk/government/news/lecanemab-393 licensed-for-adult-patients-in-the-early-stages-of-alzheimers-394 disease#:~:text=Lecanemab%20is%20a%20monoclonal%20antibody,the%20pro 395 gression%20of%20the%20disease, 2024.
- 396 4. NICE. Benefits of new Alzheimer's treatment lecanemab are too small to justify 397 the cost to the NHS. 2024; https://www.nice.org.uk/news/articles/benefits-of-new-398 alzheimer-s-treatment-lecanemab-are-too-small-to-justify-the-cost-to-the-nhs, 399 2024.
- 400 5. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and 401 care: 2024 report of the Lancet standing Commission. *Lancet.* 402 2024;404(10452):572-628.
- 403 6. Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges 404 and recommendations. *Nat Rev Drug Discov.* 2019;18(1):41-58.
- 405 7. Hughes D, Judge C, Murphy R, et al. Association of Blood Pressure Lowering 406 With Incident Dementia or Cognitive Impairment: A Systematic Review and Meta-407 analysis. *JAMA.* 2020;323(19):1934-1944.
- 408 8. Webb AJS, Birks JS, Feakins KA, et al. Cerebrovascular Effects of Sildenafil in 409 Small Vessel Disease: The OxHARP Trial. *Circ Res.* 2024;135(2):320-331.
- 410 9. Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. 411 *Vasc Health Risk Manag.* 2006;2(4):411-422.
- 412 10. Levine SB. Pharmacologic treatment of erectile dysfunction. *BMJ.* 413 2004;329(7459):E310-311.
- 414 11. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors 415 approved for the treatment of erectile dysfunction. *Circulation.* 416 2004;110(19):3149-3155.
- 417 12. Zuccarello E, Acquarone E, Calcagno E, et al. Development of novel 418 phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease. *Biochem* 419 *Pharmacol.* 2020;176:113818.
- 420 13. Fang J, Zhang P, Zhou Y, et al. Endophenotype-based in silico network medicine 421 discovery combined with insurance record data mining identifies sildenafil as a 422 candidate drug for Alzheimer's disease. *Nat Aging.* 2021;1(12):1175-1188.
- 423 14. Desai RJ, Mahesri M, Lee SB, et al. No association between initiation of 424 phosphodiesterase-5 inhibitors and risk of incident Alzheimer's disease and 425 related dementia: results from the Drug Repurposing for Effective Alzheimer's 426 Medicines study. *Brain Commun.* 2022;4(5):fcac247.
- 427 15. Schmidt AF, Finan C, Gordillo-Maranon M, et al. Genetic drug target validation 428 using Mendelian randomisation. *Nat Commun.* 2020;11(1):3255.

- 429 16. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology 430 contribute to understanding environmental determinants of disease? *Int J* 431 *Epidemiol.* 2003;32(1):1-22.
- 432 17. Gill D, Georgakis MK, Walker VM, et al. Mendelian randomization for studying 433 the effects of perturbing drug targets. *Wellcome Open Res.* 2021;6:16.
- 434 18. Schmidt AF, Hingorani AD, Finan C. Human Genomics and Drug Development. 435 *Cold Spring Harb Perspect Med.* 2022;12(2).
- 436 19. Evangelou E, Warren HR, Mosen-Ansorena D, et al. Publisher Correction: 437 Genetic analysis of over 1 million people identifies 535 new loci associated with 438 blood pressure traits. *Nat Genet.* 2018;50(12):1755.
- 439 20. Wain LV, Vaez A, Jansen R, et al. Novel Blood Pressure Locus and Gene 440 Discovery Using Genome-Wide Association Study and Expression Data Sets 441 From Blood and the Kidney. *Hypertension.* 2017;70(3):e4-e19.
- 442 21. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for 443 identifying the causes of a wide range of complex diseases of middle and old 444 age. *PLoS Med.* 2015;12(3):e1001779.
- 445 22. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 446 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat* 447 *Genet.* 2013;45(12):1452-1458.
- 448 23. de Rojas I, Moreno-Grau S, Tesi N, et al. Common variants in Alzheimer's 449 disease and risk stratification by polygenic risk scores. *Nat Commun.* 450 2021;12(1):3417.
- 451 24. Bellenguez C, Kucukali F, Jansen IE, et al. New insights into the genetic etiology 452 of Alzheimer's disease and related dementias. *Nat Genet.* 2022;54(4):412-436.
- 453 25. Wightman DP, Jansen IE, Savage JE, et al. Author Correction: A genome-wide 454 association study with 1,126,563 individuals identifies new risk loci for 455 Alzheimer's disease. *Nat Genet.* 2021;53(12):1722.
- 456 26. Sadreev II, Elsworth BL, Mitchell RE, et al. Navigating sample overlap, winner's 457 curse and weak instrument bias in Mendelian randomization studies using the 458 UK Biobank. *medRxiv.* 2021:2021.2006.2028.21259622.
- 459 27. Hinrichs AS, Karolchik D, Baertsch R, et al. The UCSC Genome Browser 460 Database: update 2006. *Nucleic Acids Res.* 2006;34(Database issue):D590-598.
- 461 28. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep 462 phenotyping and genomic data. *Nature.* 2018;562(7726):203-209.
- 463 29. Burgess S, Davey Smith G, Davies NM, et al. Guidelines for performing 464 Mendelian randomization investigations: update for summer 2023. *Wellcome* 465 *Open Res.* 2019;4:186.
- 466 30. Woolf B, Rajasundaram S, Cronje HT, Yarmolinsky J, Burgess S, Gill D. A drug 467 target for erectile dysfunction to help improve fertility, sexual activity, and 468 wellbeing: mendelian randomisation study. *BMJ.* 2023;383:e076197.
- 469 31. Burgess S, Zuber V, Valdes-Marquez E, Sun BB, Hopewell JC. Mendelian 470 randomization with fine-mapped genetic data: Choosing from large numbers of 471 correlated instrumental variables. *Genet Epidemiol.* 2017;41(8):714-725.
- 472 32. Andersen K, Launer LJ, Dewey ME, et al. Gender differences in the incidence of 473 AD and vascular dementia: The EURODEM Studies. EURODEM Incidence 474 Research Group. *Neurology.* 1999;53(9):1992-1997.

- 475 33. Woolf B, Mason A, Zagkos L, Sallis H, Munafo MR, Gill D. MRSamePopTest: 476 introducing a simple falsification test for the two-sample mendelian randomisation 477 'same population' assumption. *BMC Res Notes.* 2024;17(1):27.
- 478 34. Woolf B, Zagkos L, Gill D. TwoStepCisMR: A Novel Method and R Package for 479 Attenuating Bias in cis-Mendelian Randomization Analyses. *Genes (Basel).* 480 2022;13(9).
- 481 35. Hartwig FP, Tilling K, Davey Smith G, Lawlor DA, Borges MC. Bias in two-482 sample Mendelian randomization when using heritable covariable-adjusted 483 summary associations. *Int J Epidemiol.* 2021;50(5):1639-1650.
- 484 36. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation 485 studies: a guide, glossary, and checklist for clinicians. *BMJ.* 2018;362:k601.
- 486 37. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports 487 systematic causal inference across the human phenome. *Elife.* 2018;7.
- 488 38. Giambartolomei C, Vukcevic D, Schadt EE, et al. Bayesian test for colocalisation 489 between pairs of genetic association studies using summary statistics. *PLoS* 490 *Genet.* 2014;10(5):e1004383.
- 491 39. *dplyr: A Grammar of Data Manipulation* [computer program]. Version R package 492 version 1.1.4, https://github.com/tidyverse/dplyr2023.
- 493 40. *ggplot2: Elegant Graphics for Data Analysis* [computer program]. 2016.
- 494 41. Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the reporting of 495 observational studies in epidemiology using mendelian randomisation (STROBE-496 MR): explanation and elaboration. *BMJ.* 2021;375:n2233.
- 497 42. Tropea MR, Gulisano W, Vacanti V, Arancio O, Puzzo D, Palmeri A. Nitric 498 oxide/cGMP/CREB pathway and amyloid-beta crosstalk: From physiology to 499 Alzheimer's disease. *Free Radic Biol Med.* 2022;193(Pt 2):657-668.
- 500 43. Bollen E, Puzzo D, Rutten K, et al. Improved long-term memory via enhancing 501 cGMP-PKG signaling requires cAMP-PKA signaling. *Neuropsychopharmacology.* 502 2014;39(11):2497-2505.
- 503 44. Ota KT, Pierre VJ, Ploski JE, Queen K, Schafe GE. The NO-cGMP-PKG 504 signaling pathway regulates synaptic plasticity and fear memory consolidation in 505 the lateral amygdala via activation of ERK/MAP kinase. *Learn Mem.* 506 2008;15(10):792-805.
- 507 45. Prickaerts J, Sik A, van Staveren WC, et al. Phosphodiesterase type 5 inhibition 508 improves early memory consolidation of object information. *Neurochem Int.* 509 2004;45(6):915-928.
- 510 46. Puzzo D, Staniszewski A, Deng SX, et al. Phosphodiesterase 5 inhibition 511 improves synaptic function, memory, and amyloid-beta load in an Alzheimer's 512 disease mouse model. *J Neurosci.* 2009;29(25):8075-8086.
- 513 47. Cuadrado-Tejedor M, Hervias I, Ricobaraza A, et al. Sildenafil restores cognitive 514 function without affecting beta-amyloid burden in a mouse model of Alzheimer's 515 disease. *Br J Pharmacol.* 2011;164(8):2029-2041.
- 516 48. Hosseini-Sharifabad A, Ghahremani MH, Sabzevari O, et al. Effects of protein 517 kinase A and G inhibitors on hippocampal cholinergic markers expressions in 518 rolipram- and sildenafil-induced spatial memory improvement. *Pharmacol* 519 *Biochem Behav.* 2012;101(3):311-319.

- 520 49. Prickaerts J, van Staveren WC, Sik A, et al. Effects of two selective 521 phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object 522 recognition memory and hippocampal cyclic GMP levels in the rat. *Neuroscience.* 523 2002;113(2):351-361.
- 524 50. Palmeri A, Privitera L, Giunta S, Loreto C, Puzzo D. Inhibition of 525 phosphodiesterase-5 rescues age-related impairment of synaptic plasticity and 526 memory. *Behav Brain Res.* 2013;240:11-20.
- 527 51. Newby D. Are phosphodiesterase Type 5 inhibitors potential therapies for 528 Alzheimer's disease and related dementias? *Brain Commun.* 2022;4(5):fcac260.
- 529 52. Her QL, Kahrs JC, Sturmer T. Comparator choices in pharmacoepidemiology 530 studies of Alzheimer's disease. *Nat Aging.* 2023;3(7):791-792.
- 531 53. Adesuyan M, Jani YH, Alsugeir D, et al. Phosphodiesterase Type 5 Inhibitors in 532 Men With Erectile Dysfunction and the Risk of Alzheimer Disease: A Cohort 533 Study. *Neurology.* 2024;102(4):e209131.
- 534 54. Anderson EL, Davies NM, Korologou-Linden R, Kivimaki M. Dementia 535 prevention: the Mendelian randomisation perspective. *J Neurol Neurosurg* 536 *Psychiatry.* 2024;95(4):384-390.